Oracle (ORCL) stock jumped 2.1% in pre-market trading after William Blair added it to its Conviction List, recovering from recent losses tied to AI funding plansOracle (ORCL) stock jumped 2.1% in pre-market trading after William Blair added it to its Conviction List, recovering from recent losses tied to AI funding plans

Oracle (ORCL) Stock Gains Momentum After Inclusion on William Blair’s Conviction List

2026/07/01 21:47
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Key Highlights

  • ORCL shares advanced 2.1% during pre-market hours on July 1, 2026, rebounding from a significant downturn that brought the stock close to its yearly low of $134.57
  • The tech giant received a confidence boost as William Blair included it on their July Analyst Conviction List
  • Freedom Broker reaffirmed its Buy recommendation while adjusting the price target downward to $210 from $230, expressing caution about the company’s AI infrastructure financing strategy
  • Fourth-quarter results showed earnings per share of $2.11 on $19.18 billion revenue, surpassing projections with year-over-year revenue growth of 20.6%
  • Management’s announcement of a $40 billion capital raise through debt and equity offerings to finance AI data center expansion triggered investor concerns during the previous week

Shares of Oracle (ORCL) advanced 2.1% during Wednesday’s pre-market session on July 1, staging a comeback following one of the company’s most severe weekly declines in over two decades.


ORCL Stock Card
Oracle Corporation, ORCL

The enterprise software giant’s shares had tumbled toward their 52-week floor of $134.57 after the company disclosed its fiscal Q4 10-K report, which unveiled a substantial increase in capital spending plans and outlined intentions to secure $40 billion through combined debt and equity financing for artificial intelligence infrastructure development. This aggressive leverage strategy triggered significant investor anxiety.

Trading commenced Wednesday at $146.67. The stock’s 50-day moving average currently stands at $188.36, while the 200-day moving average rests at $174.32. The stock reached its 12-month peak at $345.72.

Wednesday’s upward movement received support from William Blair’s decision to include Oracle on its July 2026 Analyst Conviction List. Such recognition typically generates renewed interest from institutional investment firms.

Freedom Broker maintained its positive Buy stance on the shares while reducing its price objective from $230 down to $210. The brokerage recognized Oracle’s fourth-quarter performance demonstrated accelerating cloud growth and strong applications business performance, yet highlighted the pressing investor concern: can the company successfully finance its AI expansion while converting its substantial backlog into actual revenue streams?

Strong Quarterly Results Overshadowed by Strategic Concerns

Oracle delivered impressive fiscal Q4 financial results. Earnings per share reached $2.11, exceeding Wall Street’s forecast of $1.96 by $0.15. Total revenue hit $19.18 billion, surpassing the consensus estimate of $19.10 billion, representing a 20.6% increase compared to the prior year period.

Looking ahead to Q1 2027, management provided EPS guidance ranging from $1.72 to $1.76. For the complete fiscal year 2027, the company projected $8.05 in earnings per share. Current analyst consensus estimates stand at $6.45 EPS for the ongoing fiscal period.

The enterprise software company also announced its quarterly dividend distribution of $0.50 per share, scheduled for July 24 payment, with July 10 designated as the record date.

Fresh AI Solution Launch Bolsters Recovery Story

On June 30, Oracle unveiled Oracle Manager Edge, an AI-powered coaching assistant integrated within its Fusion Cloud Human Capital Management suite. Simultaneously, the company introduced new Fusion Agentic Applications designed for supply chain operations.

The company earned recognition as a leader in the IDC MarketScape assessment for AI-Enabled Utility Customer Experience Management, strengthening its enterprise AI market positioning.

Despite these encouraging developments, investor skepticism persists. The company’s ability to generate robust free cash flow will ultimately determine the success of its debt-intensive AI infrastructure strategy.

Regarding insider activity, Vice Chairman Jeffrey Henley divested 400,000 ORCL shares on June 24 at an average transaction price of $159.16, generating proceeds of $63.66 million — representing a 50% reduction in his holdings. This transaction was conducted through a predetermined Rule 10b5-1 trading arrangement.

Harbor Investment Advisory decreased its Oracle position by 25.2% during Q1, liquidating 4,221 shares. Conversely, several major institutional investors have increased exposure: Norges Bank established a new position valued above $4.3 billion in Q4, while Capital Research Global Investors expanded its Oracle holdings by 29.3%.

The consensus analyst recommendation for Oracle currently registers as “Moderate Buy” with an average price target of $268.27, substantially above present trading levels.

The post Oracle (ORCL) Stock Gains Momentum After Inclusion on William Blair’s Conviction List appeared first on Blockonomi.

Market Opportunity
Gensyn Logo
Gensyn Price(AI)
$0.03587
$0.03587$0.03587
+4.82%
USD
Gensyn (AI) Live Price Chart

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.